- Home
- URGN vs MGIC Comparison
URGN vs MGIC Comparison
Compare URGN & MGIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MGIC
- Stock Information
- Founded
- URGN 2004
- MGIC 1983
- Country
- URGN United States
- MGIC Israel
- Employees
- URGN N/A
- MGIC N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MGIC Computer Software: Prepackaged Software
- Sector
- URGN Health Care
- MGIC Technology
- Exchange
- URGN Nasdaq
- MGIC Nasdaq
- Market Cap
- URGN 830.4M
- MGIC 990.3M
- IPO Year
- URGN 2017
- MGIC 1991
- Fundamental
- Price
- URGN $16.82
- MGIC $20.98
- Analyst Decision
- URGN Strong Buy
- MGIC Buy
- Analyst Count
- URGN 8
- MGIC 2
- Target Price
- URGN $28.50
- MGIC $18.00
- AVG Volume (30 Days)
- URGN 1.2M
- MGIC 32.7K
- Earning Date
- URGN 11-05-2025
- MGIC 11-17-2025
- Dividend Yield
- URGN N/A
- MGIC 2.69%
- EPS Growth
- URGN N/A
- MGIC 16.93
- EPS
- URGN N/A
- MGIC 0.78
- Revenue
- URGN $94,238,000.00
- MGIC $584,528,000.00
- Revenue This Year
- URGN $39.63
- MGIC $11.72
- Revenue Next Year
- URGN $111.49
- MGIC $6.24
- P/E Ratio
- URGN N/A
- MGIC $26.13
- Revenue Growth
- URGN 10.85
- MGIC 11.98
- 52 Week Low
- URGN $3.42
- MGIC $10.42
- 52 Week High
- URGN $21.71
- MGIC $22.00
- Technical
- Relative Strength Index (RSI)
- URGN 42.97
- MGIC 59.00
- Support Level
- URGN $15.86
- MGIC $20.46
- Resistance Level
- URGN $17.43
- MGIC $21.47
- Average True Range (ATR)
- URGN 1.06
- MGIC 0.52
- MACD
- URGN -0.15
- MGIC 0.12
- Stochastic Oscillator
- URGN 23.05
- MGIC 80.29
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MGIC Magic Software Enterprises Ltd.
Magic Software Enterprises Ltd is a software development company. The company's operating segment includes Software Services and IT Professional Services. The company generates maximum revenue from the IT Professional Services segment. IT Professional Services segment offers IT services in the areas of infrastructure design and delivery, application development, technology planning and implementation services, communications services and solutions, as well as supplemental outsourcing services. Geographically, it derives a majority of revenue from the United States and also has a presence in Israel, Europe, Japan, and Other countries.